A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid arthritis or systemic lupus erythematosus.

2025-522273-10-00 Protocol D740AC00001 Human pharmacology (Phase I) - Other Authorised, recruiting

Start 24 Feb 2026 · Status Authorised, recruiting · 3 EU/EEA countries · 11 sites · Protocol D740AC00001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruiting
Participants planned 48
Countries 3
Sites 11

Systemic Lupus Erythematosus

Key facts

Sponsor
AstraZeneca AB
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05], Diseases [C] - Immune System Diseases [C20]
Trial duration
24 Feb 2026 → ongoing
Decision date (initial)
2026-02-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2025-522273-10-00
ClinicalTrials.gov
NCT07201558

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Systemic Lupus Erythematosus

VersionLevelCodeTermSystem organ class
23.1 PT 10039073 Rheumatoid arthritis 100000004859
21.1 PT 10042945 Systemic lupus erythematosus 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstraZeneca AB

Sponsor organisation
AstraZeneca AB
Address
-
City
Sodertalje
Postcode
151 85
Country
Sweden

Scientific contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Public contact point

Organisation
AstraZeneca AB
Contact name
Clinical Study Information Center

Locations

3 EU/EEA countries · 11 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Authorised, recruiting 5 4
Germany Authorised, recruiting 5 4
Spain Authorised, recruiting 5 3
Rest of world
United States, Australia, Taiwan, China, Brazil, Ukraine, United Kingdom
33

Investigational sites

Belgium

4 sites · Authorised, recruiting
Ziekenhuis Aan De Stroom
Department of rheumatology, Lange Bremstraat 70, 2170, Antwerp
Universitair Ziekenhuis Antwerpen
Department of immunology, allergology and rheumatology, Drie Eikenstraat 655, 2650, Edegem
Centre hospitalier universitaire de Liege
Department of rheumatology, Avenue De L'Hopital 1, 4000, Liege
Ziekenhuis Aan De Stroom
Department of rheumatology, Kempenstraat 100, 2030, Antwerp

Germany

4 sites · Authorised, recruiting
Universitaetsklinikum Bonn AöR
Rheumatology, Venusberg-Campus 1, Venusberg, Bonn
LMU Klinikum Muenchen AöR
Medizinische Klinik und Poliklinik IV Sektion Rheumatologie und klinische Immunologie–Studienambu, Pettenkoferstrasse 8a, Ludwigsvorstadt-Isarvorstadt, Munich
Universitaetsklinikum Jena KöR
Klinik für Innere Medizin III Rheumazentrum (G-BA-Kriterien) sowie Sektion Rheumatologie und Osteol, Am Klinikum 1, Lobeda, Jena
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Med. Klinik und Poliklinik Nephrology, Langenbeckstrasse 1, Oberstadt, Mainz

Spain

3 sites · Authorised, recruiting
Hospital Universitario Ramon Y Cajal
Rheumatology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital De La Santa Creu I Sant Pau
Rheumatology, Carrer De San Quinti 89, 08041, Barcelona
Hospital Universitario Reina Sofia
Rheumatology, Avenida Menendez Pidal S/n, 14004, Cordoba

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2026-03-27
Germany 2026-04-24
Spain 2026-02-24

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-15 Spain Acceptable
2026-02-02
2026-02-03